FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:1160 April 16, 1998 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Epidemics of hepatitis A occurred in four of the six years preceding the Monroe efficacy trial ¹ of an inactivated hepatitis A vaccine (VAQTA).² Post-trial surveillance included semiannual household telephone surveys, county disease-report surveys, and physical examinations, and -glutamyltransferase and IgM antibody tests in suspected cases. In six post-trial years, despite sporadic cases in people who were not vaccinated, Monroe has had no hepatitis A outbreaks or cases among vaccinated people, whereas in three similar, unvaccinated neighboring communities the combined annual cases for 1993 through 1997 totaled 31, 38, 106, 53, and 6. Our data suggest the degree . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Karayiannis, P., Main, J., Thomas, H. C. (2004). Hepatitis vaccines. Br Med Bull 70: 29-49 [Full Text]  
• (2002). Jaundice in primary school pupils. Postgrad. Med. J. 78: 59-60 [Full Text]  
• Thomas, M. P., Nalin, D. R. (1998). Hepatitis A Vaccination. NEJM 339: 705-705 [Full Text]